vertex pharmaceuticals casgevy

Vertex Pharmaceuticals, FDA

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November,

Seeking Alpha · 2d

Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

FOX News on MSN · 2d

Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).

Hosted on MSN · 12h

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).

Investor's Business Daily on MSN · 2d

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Vertex Pharmaceuticals announces Casgevy reimbursement pact with NHS England

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

PMLiVE2d

NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Vertex Pharmaceuticals Shares Are Up Today: What's Going On?

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Yahoo Finance2d

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

LONDON, January 31, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to ...

Pharmaceutical Technology on MSN2d

NHS England to offer Casgevy for sickle cell disease patients

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

2don MSN

Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results